We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

56 hedge funds and large institutions have $236M invested in Gyre Therapeutics in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 18 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 2

496% more capital invested

Capital invested by funds: $39.7M → $236M (+$197M)

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

300% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 7

60% more funds holding

Funds holding: 35 → 56 (+21)

3.61% more ownership

Funds ownership: 6.66% → 10.27% (+3.6%)

55% less call options, than puts

Call options by funds: $2.29M | Put options by funds: $5.15M

Holders
56
Holders Change
+21
Holders Change %
+60%
% of All Funds
1.28%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.11%
New
28
Increased
18
Reduced
2
Closed
7
Calls
$2.29M
Puts
$5.15M
Net Calls
-$2.86M
Net Calls Change
-$2.86M

Top Buyers

1
SCM
Sio Capital Management
New York
+$23.6M
2
DM
Deerfield Management
New York
+$20.7M
3
ACP
Acuta Capital Partners
California
+$17.5M
4
ACA
Avoro Capital Advisors
New York
+$15.5M
5
RCM
RA Capital Management
Massachusetts
+$12.8M

Top Sellers

1
PVI
Pura Vida Investments
New York
-$818K
2
RJA
Raymond James & Associates
Florida
-$585K
3
UBS Group
UBS Group
Switzerland
-$583K
4
BRWA
B. Riley Wealth Advisors
Florida
-$510K
5
KM
Kalos Management
Georgia
-$222K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$799K +$223K +1,198 +41%
Morgan Stanley
27
Morgan Stanley
New York
$792K +$682K +3,657 +843%
SSA
28
Schonfeld Strategic Advisors
New York
$693K +$668K +3,583 New
Northern Trust
29
Northern Trust
Illinois
$659K +$303K +1,623 +91%
EGI
30
EAM Global Investors
California
$644K +$621K +3,330 New
BFM
31
Boothbay Fund Management
New York
$636K +$613K +3,287 New
TEE
32
Tibra Equities Europe
United Kingdom
$587K +$566K +3,035 New
VF
33
Virtu Financial
New York
$568K +$547K +2,933 New
Invesco
34
Invesco
Georgia
$483K +$466K +2,500 New
Two Sigma Investments
35
Two Sigma Investments
New York
$467K +$450K +2,412 New
EMG
36
Ellington Management Group
Connecticut
$433K +$418K +2,240 New
Deutsche Bank
37
Deutsche Bank
Germany
$405K +$387K +2,073 +10,365%
SIM
38
Spark Investment Management
New York
$330K +$318K +1,707 New
Simplex Trading
39
Simplex Trading
Illinois
$325K +$313K +1,680 New
BCM
40
BlueCrest Capital Management
Jersey
$308K +$297K +1,590 New
Wells Fargo
41
Wells Fargo
California
$231K +$133K +712 +148%
State Street
42
State Street
Massachusetts
$221K +$213K +1,142 New
Barclays
43
Barclays
United Kingdom
$76K +$64.7K +347 +789%
Bank of America
44
Bank of America
North Carolina
$59K +$56.3K +302 +7,550%
UBS Group
45
UBS Group
Switzerland
$34K -$583K -3,126 -95%
Group One Trading
46
Group One Trading
Illinois
$31K +$30K +161 +16,100%
CG
47
Cutler Group
California
$30K +$29.8K +160 New
FANJ
48
Financial Architects (New Jersey)
New Jersey
$15K +$14.9K +80 New
SFM
49
Signet Financial Management
New Jersey
$10K +$9.89K +53 New
TDC
50
Thompson Davis & Co
Virginia
$3K – – –
1
2
3

GYRE Hedge Fund Activity: Q1 2018 in Review

56 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2018, worth a combined $236M — up 496% from $39.7M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new GYRE positions and 7 closed out — a net gain of 21 holders — while 18 added to existing stakes and 2 trimmed.

The largest buyer was Sio Capital Management, adding an estimated $23.6M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $818K sold.

  • 56 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2018, up from 35 in Q4 2017.
  • Funds reported $236M of Gyre Therapeutics stock for Q1 2018, up 496% quarter-over-quarter.
  • 28 funds opened new Gyre Therapeutics positions in Q1 2018 and 7 closed out, a net change of +21 holders.
  • The largest Gyre Therapeutics buyer in Q1 2018 was Sio Capital Management, an estimated $23.6M added.
  • The largest Gyre Therapeutics seller in Q1 2018 was Pura Vida Investments, an estimated $818K sold.

Based on aggregated 13F filings for Q1 2018.